Mesalamine for inflammatory bowel disease: recent reappraisals
Giovanni C Actis1, Paola Pazienza, Floriano Rosina
1Department of Gastro-Hepatology, Ospedale Gradenigo, Torino, Italy. actis_g@libero.it
Inflammation & Allergy Drug Targets
|May 14, 2008
Summary
Mesalamine, a key treatment for inflammatory bowel disease, shows new promise in preventing colorectal cancer and enhancing thiopurine effectiveness. Higher doses (4.8g daily) are now recommended for optimal results.
Area of Science:
- Gastroenterology
- Pharmacology
- Oncology
Background:
- Mesalamine has been a primary treatment for inflammatory bowel disease (IBD) for 50 years.
- Recent research re-evaluates mesalamine's role in colorectal cancer chemoprevention and its interaction with thiopurine therapy for ulcerative colitis.
Purpose of the Study:
- To explore the re-emerging indications for mesalamine in IBD management.
- To investigate mesalamine's chemoprotective effects against sporadic colorectal cancer.
- To understand mesalamine's influence on thiopurine metabolism and efficacy in ulcerative colitis.
Main Methods:
- Review of clinical trials and basic research on mesalamine.
- Analysis of mesalamine's molecular mechanisms in apoptosis and inflammation.
- Investigation of mesalamine's impact on thiopurine metabolism in patients with ulcerative colitis.
Main Results:
- Mesalamine demonstrates chemoprotective effects against colorectal cancer by enhancing apoptosis.
- Mesalamine can increase blood concentrations of immunosuppressive thiopurine metabolites, improving drug effectiveness.
- Higher mesalamine dosages (4.8g/day) are more effective than traditional doses (2.4g/day).
Conclusions:
- Mesalamine's indications are expanding beyond IBD to include colorectal cancer chemoprevention.
- Mesalamine can overcome genetic resistance to thiopurines by optimizing their metabolism.
- Optimized dosing and novel formulations (multi-matrix systems) improve mesalamine efficacy and patient compliance in IBD treatment.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...